Can a Two-Drug Treatment Regimen Keep HIV Under Control?
August 9, 2016
An antiretroviral regimen consisting of just two drugs -- dolutegravir and lamivudine -- led to sustained viral suppression for most people starting HIV treatment for the first time, according to findings from a small study presented in a late-breaker session at the recent 21st International AIDS Conference (AIDS 2016) in Durban, South Africa. Two-drug regimens would potentially be easier to take and less expensive compared to the standard three-drug HIV treatment regimens.
ViiV Healthcare's drug dolutegravir (Tivicay, also in the Triumeq combination pill) is a potent HIV integrase inhibitor with a high barrier to resistance. Lamivudine (3TC or Epivir) is an inexpensive nucleoside reverse transcriptase inhibitor (NRTI) with minimal side effects and no known drug interactions.
Pedro Cahn, M.D., from Fundacion HUESPED in Buenos Aires reported findings from the PADDLE trial, a small proof-of-concept study evaluating dolutegravir plus lamivudine for first-line HIV treatment (abstract FRAB0104LB).
This excerpt was cross-posted with the permission of BETAblog.org. Read the full article.
This article was provided by BETA. It is a part of the publication The 21st International AIDS Conference (AIDS 2016). Visit their website at www.betablog.org.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.